MannKind | MNKD - Ebitda

Stock Price
5.68
Daily Change
0.11 1.89%
Monthly
1.70%
Yearly
0.44%
Q1 Forecast
5.37

MannKind reported $9.75M in EBITDA for its fiscal quarter ending in June of 2025.





Ebitda Change Date
Adma Biologics USD 58.74M 14.75M Sep/2025
Eli Lilly USD 7.88B 378.1M Sep/2025
Halozyme Therapeutics USD 21.9M 226.34M Dec/2025
Insmed USD -314.19M 31.48M Dec/2025
Karyopharm Therapeutics USD -26.2M 1.83M Sep/2024
MacroGenics USD 21.95M 55.39M Sep/2025
MannKind USD 9.75M 17.66M Jun/2025
Merck USD 8.39B 1.97B Sep/2025
Minerva Neurosciences USD -4.36M 1.71M Sep/2024
Novavax USD -117.12M 55.66M Sep/2024
Novo Nordisk DKK 31.44B 6.84B Sep/2025
Pfizer USD 6.08B 351M Sep/2025
Sanofi EUR 4.84B 2.95B Sep/2025
Xencor USD -30.52M 6.39M Jun/2025